抗ige治疗哮喘

Asthma Magazine Pub Date : 2005-05-01 DOI:10.1016/S1088-0712(05)00043-9

Susan Berg

{"title":"抗ige治疗哮喘","authors":"Susan Berg","doi":"10.1016/S1088-0712(05)00043-9","DOIUrl":null,"url":null,"abstract":"<div><p><span>In June 2003, Xolair, the first anti-IgE medication, received FDA approval, bringing hope and relief to adults and adolescents (12 years and over) with uncontrolled allergic asthma. Xolair has been touted as a breakthrough treatment for asthma, and rightly so. In two pivotal clinical trials, Xolair reduced asthma attacks by half and improved patients' asthma symptoms and ability to breathe (</span><em>J Allergy Clin Immun</em> 2001;108:184-190, and <em>Eur Respi</em>r J 2001;18:254-261). Furthermore, study participants who took Xolair were able to decrease, and in some cases even eliminate, the daily required dose of inhaled corticosteroids.</p></div>","PeriodicalId":100135,"journal":{"name":"Asthma Magazine","volume":"10 3","pages":"Pages 22-24"},"PeriodicalIF":0.0000,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1088-0712(05)00043-9","citationCount":"0","resultStr":"{\"title\":\"Anti-IgE therapy for asthma\",\"authors\":\"Susan Berg\",\"doi\":\"10.1016/S1088-0712(05)00043-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>In June 2003, Xolair, the first anti-IgE medication, received FDA approval, bringing hope and relief to adults and adolescents (12 years and over) with uncontrolled allergic asthma. Xolair has been touted as a breakthrough treatment for asthma, and rightly so. In two pivotal clinical trials, Xolair reduced asthma attacks by half and improved patients' asthma symptoms and ability to breathe (</span><em>J Allergy Clin Immun</em> 2001;108:184-190, and <em>Eur Respi</em>r J 2001;18:254-261). Furthermore, study participants who took Xolair were able to decrease, and in some cases even eliminate, the daily required dose of inhaled corticosteroids.</p></div>\",\"PeriodicalId\":100135,\"journal\":{\"name\":\"Asthma Magazine\",\"volume\":\"10 3\",\"pages\":\"Pages 22-24\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1088-0712(05)00043-9\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asthma Magazine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1088071205000439\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asthma Magazine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1088071205000439","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

2003年6月，首个抗ige药物Xolair获得FDA批准，为患有未控制的过敏性哮喘的成人和青少年(12岁及以上)带来了希望和缓解。Xolair被吹捧为治疗哮喘的突破性药物，这是正确的。在两项关键的临床试验中，Xolair减少了一半的哮喘发作，改善了患者的哮喘症状和呼吸能力(J Allergy clinimmun 2001;108:184-190; Eur Respir J 2001;18:254-261)。此外，服用Xolair的研究参与者能够减少，在某些情况下甚至消除每日吸入皮质类固醇的所需剂量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Anti-IgE therapy for asthma

In June 2003, Xolair, the first anti-IgE medication, received FDA approval, bringing hope and relief to adults and adolescents (12 years and over) with uncontrolled allergic asthma. Xolair has been touted as a breakthrough treatment for asthma, and rightly so. In two pivotal clinical trials, Xolair reduced asthma attacks by half and improved patients' asthma symptoms and ability to breathe (J Allergy Clin Immun 2001;108:184-190, and Eur Respir J 2001;18:254-261). Furthermore, study participants who took Xolair were able to decrease, and in some cases even eliminate, the daily required dose of inhaled corticosteroids.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助